CPA inhibitors are research compounds primarily used to inhibit the activity of Carboxypeptidase A (CPA) enzymes, which are involved in protein digestion and various biological processes. They are employed in biochemical and pharmacological studies to explore enzyme functions and develop potential therapeutics for conditions associated with enzyme dysregulation, such as cancer, inflammatory diseases, and neurological disorders.

In oncology research, CPA inhibitors help investigate metabolic pathways related to cell proliferation and tumor growth, aiding in the design of anti-cancer agents. They are also studied for modulating immune responses in inflammation models, with applications in arthritis and autoimmune conditions.

Ongoing research examines their potential in overcoming drug resistance and enhancing combination therapies, though they are not yet standard treatments but valuable tools in drug discovery.